Impairment Losses - The total impairment loss for the year ended December 31, 2022, amounted to RMB 1,727,119,000[1]. - The impairment losses by business segment include RMB 976,588,000 for the generic drugs segment, RMB 314,455,000 for innovative drugs and other products, and RMB 436,076,000 for unallocated amounts[2]. - The impairment in the generic drugs segment was primarily due to the impact of centralized procurement policies and the inclusion of more products in the key drug monitoring catalog[2]. - The company recognized an impairment loss of RMB 3,912,000 related to certain ongoing product development projects that were deemed to have low future returns[3]. - The impairment review and valuation were based on cash flow forecasts approved by management, reflecting specific risks associated with the business[4]. - The company conducts annual asset impairment assessments and will perform more frequent evaluations if events indicate potential impairments[2]. Centralized Procurement Policies - Management adjusted revenue and gross margin forecasts due to the ongoing implementation of centralized procurement policies affecting multiple cash-generating units[5]. - The anticipated full implementation of the seventh batch of centralized procurement policies is expected to have immediate pricing impacts on generic drug products[5]. - The company noted that the inclusion of products in the key drug monitoring catalog negatively affects sales volumes, particularly for generic and raw materials drugs[5]. - Supply chain disruptions and rising raw material and transportation costs due to the pandemic have significantly impacted the cash-generating units in the generic and raw materials drug segments[5].
四环医药(00460) - 2022 - 年度业绩